La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Xbrane Biopharma Crescita futura

Future criteri di controllo 6/6

Xbrane Biopharma prevede che gli utili e i ricavi cresceranno rispettivamente di 105.2% e 58.4% all'anno. Si prevede che l'EPS crescerà di 119.5% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 53.3% in 3 anni.

Informazioni chiave

99.8%

Tasso di crescita degli utili

129.5%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	45.2%
Tasso di crescita dei ricavi	58.8%
Rendimento futuro del capitale proprio	53.3%
Copertura analitica	Low
Ultimo aggiornamento	23 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Aug 05

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

Jun 21

Xbrane Biopharma AB (publ)'s (STO:XBRANE) Intrinsic Value Is Potentially 28% Above Its Share Price

Feb 10

We Think Xbrane Biopharma (STO:XBRANE) Can Afford To Drive Business Growth

Jan 12

What Kind Of Investors Own Most Of Xbrane Biopharma AB (publ) (STO:XBRANE)?

Dec 16

Insider Buying: The Xbrane Biopharma AB (publ) (STO:XBRANE) Head of Manufacturing & Supply Chain Just Bought 50% More Shares

Nov 20

Previsioni di crescita degli utili e dei ricavi

OM:XBRANE - Stime future degli analisti e dati finanziari passati (SEK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	1,122	644	N/A	N/A	2
12/31/2025	680	104	320	329	2
12/31/2024	315	-271	-43	-13	1
3/31/2024	191	-361	-465	-463	N/A
12/31/2023	239	-322	-423	-407	N/A
9/30/2023	189	-285	-467	-441	N/A
6/30/2023	144	-246	-427	-389	N/A
3/31/2023	112	-189	-340	-296	N/A
12/31/2022	58	-169	-254	-194	N/A
9/30/2022	43	-146	-216	-139	N/A
6/30/2022	32	-147	-229	-127	N/A
3/31/2022	15	-172	-282	-182	N/A
12/31/2021	11	-183	-297	-220	N/A
9/30/2021	8	-213	-278	-227	N/A
6/30/2021	5	-219	-286	-268	N/A
3/31/2021	3	-215	-160	-147	N/A
12/31/2020	N/A	-218	-242	-238	N/A
9/30/2020	N/A	-222	-169	-165	N/A
6/30/2020	N/A	-210	-146	-145	N/A
3/31/2020	N/A	-204	-180	-179	N/A
12/31/2019	N/A	-188	-150	-149	N/A
9/30/2019	5	-154	-118	-117	N/A
6/30/2019	7	-56	0	2	N/A
3/31/2019	12	-40	0	2	N/A
12/31/2018	20	-13	45	47	N/A
9/30/2018	25	0	-8	-4	N/A
6/30/2018	23	-69	-51	-47	N/A
3/31/2018	23	-45	-40	-36	N/A
12/31/2017	21	-45	N/A	-37	N/A
9/30/2017	11	-35	N/A	-35	N/A
6/30/2017	11	-34	N/A	-39	N/A
3/31/2017	6	-31	N/A	-41	N/A
12/31/2016	N/A	-28	N/A	-39	N/A
9/30/2016	0	-24	N/A	-37	N/A
6/30/2016	0	-19	N/A	-27	N/A
3/31/2016	1	-16	N/A	-19	N/A
12/31/2015	0	-12	N/A	-12	N/A
9/30/2015	2	-8	N/A	-5	N/A
12/31/2014	2	-3	N/A	-3	N/A
12/31/2013	0	-2	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che XBRANE diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 1.1% ).

Guadagni vs Mercato: Si prevede che XBRANE diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede XBRANE diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di XBRANE ( 58.4% all'anno) crescerà più rapidamente del mercato Swedish ( 1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di XBRANE ( 58.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di XBRANE sarà molto alto tra 3 anni ( 53.3 %).

Xbrane Biopharma Crescita futura

Future criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 35%

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

Recent updates

Market Cool On Xbrane Biopharma AB (publ)'s (STO:XBRANE) Revenues Pushing Shares 34% Lower

Market Might Still Lack Some Conviction On Xbrane Biopharma AB (publ) (STO:XBRANE) Even After 32% Share Price Boost

First quarter 2024 earnings: Revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report Q2, 2024 Results on Aug 28, 2024

Xbrane Biopharma AB (Publ) Appoints Kristoffer Bissessar Was Elected as New Director

Consensus EPS estimates fall by 35%

New minor risk - Financial position

New major risk - Shareholder dilution

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Market cap size

Xbrane Biopharma AB (Publ) Announces Appointment of Nomination Committee

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) Focuses on Development Portfolio and Introduces A Cost-Savings Scheme

Xbrane Biopharma AB (publ) to Report First Half, 2024 Results on Jul 17, 2024

Xbrane Biopharma AB (Publ) Presents Nomination Committee

Chief Executive Officer recently sold kr272k worth of stock

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 28%

Forecast breakeven date pushed back to 2025

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target increased by 37% to kr219

Consensus revenue estimates increase by 14%, EPS downgraded

Price target increased by 13% to kr253

New major risk - Financial position

Chief Executive Officer recently bought kr150k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr817k worth of stock

Xbrane Biopharma AB (publ) to Report Fiscal Year 2023 Results on Feb 29, 2024

CFO & Head of Investor Relations recently bought kr236k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 15%

Now 22% undervalued

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 04, 2023

Insider recently bought kr156k worth of stock

Chief Executive Officer recently bought kr175k worth of stock

Xbrane Provides an Update on Ranibizumab Biosimilar Candidate FDA Filing

Forecast breakeven date pushed back to 2024

Price target increased to kr173

STADA Arzneimittel AG and Xbrane Biopharma AB Secures EU Approval for Ximluci (Ranibizumab) Biosimilar Referencing Lucentis

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Xbrane Biopharma AB (publ) to Report First Half, 2023 Results on Aug 31, 2023

STADA Arzneimittel AG and Xbrane Biopharma AB (publ) Announce European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion for Ximluci

Xbrane Biopharma AB (publ), Annual General Meeting, May 04, 2023

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xbrane Biopharma AB (publ) to Report Q1, 2023 Results on May 31, 2023

Xbrane Biopharma AB (publ) to Report Fiscal Year 2022 Final Results on Mar 31, 2023

Xbrane Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Chief Executive Officer recently sold kr1.0m worth of stock

An unknown buyer acquired an unknown minority stake in Xbrane Biopharma AB (publ) (OM:XBRANE) from Martin Amark and Siavash Bashiri.

Head of Regulatory Affairs recently bought kr104k worth of stock

Chief Technology Officer recently bought kr699k worth of stock

Is Xbrane Biopharma (STO:XBRANE) In A Good Position To Deliver On Growth Plans?

Xbrane Biopharma AB (publ) Provides Update on Ranibizumab Biosimilar Candidate FDA Filing

Price target increased to kr235

Chief Executive Officer recently sold kr496k worth of stock

Xbrane Biopharma AB (Publ) Announces Positive Top-Line Results from the Pivotal Phase III Equivalence Trial for Xlucane™ - A Biosimilar Candidate to Lucentis

Xbrane Biopharma AB (publ)(OM:XBRANE) dropped from OMX Nordic Small Cap Index

We Think Xbrane Biopharma (STO:XBRANE) Needs To Drive Business Growth Carefully

Consensus EPS estimates increase to -kr9.83

Forecast to breakeven in 2023

Head of Regulatory Affairs recently bought kr125k worth of stock

COO, Head of Biosimilars & Deputy CEO recently bought kr368k worth of stock

Chief Executive Officer recently sold kr172k worth of stock

Market Sentiment Around Loss-Making Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB (publ) Appoints Erik Domines as General Counsel

Xbrane Biopharma AB (publ) (STO:XBRANE) Insiders Increased Their Holdings

New 90-day high: kr108

Xbrane Biopharma AB (publ) to Report Fiscal Year 2021 Results on Feb 16, 2022